Home - atai Life Sciences

Redefining how the world approaches, prevents, and heals mental health disorders.

We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.

LEARN MORE

For everyone, everywhere

Led by the brightest minds in the industry

atai is home to some of the most sought-after executives and scientists in the space. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms.

Our People

Guided by a noble mission

We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.

Our Mission

Our unique operating model

Our approach combines funding, access to accelerative platform technologies, as well as scientific and regulatory expertise with a singular focus on developing more rapid-acting and potentially disease-modifying mental health treatments.

Our Model

OUR PERSPECTIVE

Shortcomings of existing therapies

Current standard of care treatments are ineffective for millions worldwide.

Significant burden

~1bn

Affected People

Global population with mental health disorders

>50%

Of US population impacted

Expected that more than half of US population will have a mental health disorder at some point in their lifetime

~$16tn

Global economic impact

Estimated global economic costs of mental health disorders by 2030

~4x

Recent impact of COVID-19

Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020

Urgent need for innovation

~33%

Respond inadequately

A third of patients with depression respond inadequately or relapse with current treatments within certain indications

Up to 12 wks

Slow onset of treatment effect

Frontline treatments for depression and anxiety have slow onset (4-12w)

~75%

Relapse rate

Most of the patients treated for opioid use disorder (OUD) relapse

Psychiatry approvals since 2015

Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107)

Our unique approach

Compounds with prior evidence in humans

To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.

https://secureservercdn.net/160.153.138.42/96y.19f.myftpupload.com/wp-content/uploads/2020/11/home-1b.png?time=1664548822

Enabling platform technologies

Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics.

https://secureservercdn.net/160.153.138.42/96y.19f.myftpupload.com/wp-content/uploads/2020/11/home-2b.png?time=1664548822

Decentralized drug development

In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.

https://secureservercdn.net/160.153.138.42/96y.19f.myftpupload.com/wp-content/uploads/2020/11/home-3b.png?time=1664548822

Learn more about our approach

OUR MODEL

WHERE WE’RE HEADED

Our technologies drive efficient drug discovery and improved treatment outcomes.

Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.

OUR MODEL

News & Insights

News

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics…

September 27, 2022

7:24 am

Articles

atai Life Sciences to Participate in September Investor Events

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…

September 7, 2022

9:20 am